Outcome of intravitreal Avastin® injections in patients with macular oedema in Uganda: a cohort study

Simple item page
dc.contributor.authorKabunga, Rachel R.
dc.contributor.authorOnyango, John
dc.contributor.authorRuvuma, Sam
dc.contributor.authorArunga, Simon
dc.date.accessioned2023-03-26T18:36:42Z
dc.date.available2023-03-26T18:36:42Z
dc.date.issued2022
dc.description.abstractTo determine the outcome of Intravitreal Avastin (IVA) injections in patients with Macular Oedema (MO) in Uganda. METHODS: We prospectively recruited patients presenting with MO at the Department of Ophthalmology of Mbarara University of Science and Technology in Southern Uganda from November 2018 to April 2019. We treated them with intravitreal injection of Bevacizumab (Avastin®) and followed them up for three consecutive months after the initial injection. We collected information on baseline clinical presentation and 3 month outcomes. We performed a Student’s t-test to compare central macular thickness (CMT) and best corrected visual acuity (BCVA) at baseline and at 3 months after IVA injections. We performed linear regression to test for predictors of change in CMT and BCVA at 3 months. RESULTS: We enroled 32 patients (35 eyes) of which 29 patients (32 eyes) completed the follow up. The mean age was 62.8 ± 11.8 years, and 53% were male. At 3 months after IVA, the mean CMT improved significantly from 426.90 ± 135.9 μm at baseline to 311.20 ± 134.80 μm (p = 0.0008). The mean BCVA improved from 0.70 ± 0.38 at baseline to 0.38 ± 0.36 logMAR units (p = 0.003). The improvement in CMT and BCVA were more marked in patients who had Diabetic ME compared to other causes. A high baseline CMT was a strong predictor of improvement in CMT at 3 months after IVA therapy. A worse baseline visual acuity was a predictor of improvement in vision at 3 months after IVA. CONCLUSIONS: IVA therapy results in anatomical and visual improvement at 3 months especially in patients with Diabetic MO. Having a high baseline CMT was a predictor of good CMT outcome at 3 months while a worse vision at baseline was a predictor of better visual outcome at 3 months.en_US
dc.identifier.citationKabunga, R. R., Onyango, J., Ruvuma, S., & Arunga, S. (2022). Outcome of intravitreal Avastin® injections in patients with macular oedema in Uganda: a cohort study. Eye, 36(Suppl 1), 45-50. https://doi.org/10.1038/s41433-022-02006-5en_US
dc.identifier.urihttps://doi.org/10.1038/s41433-022-02006-5
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/8293
dc.language.isoenen_US
dc.publisherEyeen_US
dc.subjectIntravitreal Avastinen_US
dc.subjectInjectionsen_US
dc.subjectPatientsen_US
dc.subjectMacular oedemaen_US
dc.titleOutcome of intravitreal Avastin® injections in patients with macular oedema in Uganda: a cohort studyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Outcome of intravitreal Avastin® injections in patients with.pdf
Size:
585.67 KB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences